India-EU trade pact nears, as generic drug row 'resolved' at Brussels summit meeting

13 December 2010

European Commission president Jose Manuel Barroso revealed last Friday that a trade and investment agreement between the European Union and India would be concluded in the first part of next year. Negotiations for such a Free Trade Agreement (FTA) were launched in June 2007.

Speaking at a press conference after an EU-India summit in Brussels, Belgium, on December 10, Mr Barroso said: “Today, we have agreed on the basic contours of an ambitious agreement, and to give the final political push to these talks. Our aim is to conclude negotiations next spring or in any case as early as possible during 2011.”

In a joint statement, Indian Prime Minister Manmohan Singh, European Council President Herman Van Rompuy and Mr Barroso said they looked forward to a free trade agreement (FTA) being concluded in the spring. But some problems remain in finalizing the accord that is expected to boost the two-way business volume between the countries to 100 billion euros ($133.8 billion) from 77 billion euros presently.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics